Company intelligence / Profile preview
Affymax, Inc.
New York, New York, United Statesaffymax.com ↗
- Ownership
- Public · AFFY
- Employees
- ~2
- Development stage
- Other
01
Overview
Previously developed Omontys, an anemia drug that was recalled in 2013 due to serious hypersensitivity reactions including patient deaths. The drug was not permitted to return to the market, and the company decided to dissolve in 2014[1][4].
- Therapeutic areas
- Nephrology
- Modalities
- Small molecules (inferred from combinatorial chemistry background)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Previously partnered with Takeda (dissolved in 2014)[1]
04
Financials
- Market cap
- $30K
- Total revenue
- $1.4M
- Enterprise value
- $-3.4M
Beyond the preview
Go deeper on Affymax, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Affymax, Inc..